Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia

International Journal of Drug Policy

Volumn 26, Issue 10, 2015, Pages 992-998

  Treloar, Carla ^a   Rance, Jake ^a   Bath, Nicky ^b   Everingham, Hope ^b   Micallef, Michelle ^c   Day, Carolyn ^d,e   Hazelwood, Sue ^f   Grebely, Jason ^c   Dore, Gregory J ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b NSW Users and AIDS Association   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f Drug and Alcohol Clinical Services   (Australia)

Author keywords

Hepatitis C; Peer support; People who inject drugs; Qualitative; Treatment

Indexed keywords

ADULT; ANTIVIRAL THERAPY; ARTICLE; AUSTRALIA; CLINICAL TRIAL; CONFIDENTIALITY; DRUG DEPENDENCE; FEMALE; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE FACILITY; HEALTH PERSONNEL ATTITUDE; HEALTH PROGRAM; HEALTH SERVICE; HEPATITIS C; HUMAN; INTRAVENOUS DRUG ABUSE; MALE; MEDICAL STAFF; MULTICENTER STUDY; NURSE PATIENT RELATIONSHIP; OPIATE SUBSTITUTION TREATMENT; PATIENT PARTICIPATION; PEER GROUP; PERFORMANCE MEASUREMENT SYSTEM; PRIORITY JOURNAL; PROGRAM EVALUATION; SEMI STRUCTURED INTERVIEW; SOCIAL INTERACTION; SOCIAL SUPPORT; TRUST; COMPLICATION; DRUG DEPENDENCE TREATMENT; DRUG THERAPY; MIDDLE AGED; PATIENT SATISFACTION; PROCEDURES; SUBSTANCE ABUSE;

ADULT; ATTITUDE OF HEALTH PERSONNEL; AUSTRALIA; FEMALE; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; PATIENT SATISFACTION; PEER GROUP; PROGRAM EVALUATION; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84941803449     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2015.01.005     Document Type: Article

References (32)

1. Alavi M., Grebely J., Micallef M., Dunlop A., Balcomb A., Day C., et al. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opiate substitution setting: The ETHOS study. Clinical Infectious Diseases 2013, 57(S2):S62-S69.
2. Baker D., Alavi M., Erratt A., Hill S., Balcomb A., Hallinan R., et al. Delivery of treatment for hepatitis C virus infection in the primary care setting. European Journal of Gastroenterology and Hepatology 2014, 26(9):1003-1009.
3. Bruggmann P., Litwin A. Models of care for the management of HCV among people who use drugs: One size does not fit all. Clinical Infectious Diseases 2013, 57(S2):S56-S61.
4. Burhansstipanov L., Bad Wound D., Capelouto N., Goldfarb F., Harjo L., Hatathlie L., et al. Culturally relevant "navigator" patient support the native sisters. Cancer Practice 1998, 6(3):191-194.
5. Casey L., Lee W. Hepatitis C virus therapy update 2013. Current Opinion in Gastroenterology 2013, 29:243-249.
6. Crawford S. Shouting through bullet-proof glass: some reflections on pharmacotherapy provision in one Australian clinic. International Journal of Drug Policy 2013, 24(6):e14-17.
7. Crawford S., Bath N. Peer support models for people with a history of injecting drug use undertaking assessment and treatment for hepatitis C virus infection. Clinical Infectious Diseases 2013, 57(S2):S75-S79.
8. Fraser S. The chronotope of the queue: Methadone maintenance treatment and the production of time, space and subjects. International Journal of Drug Policy 2006, 17:192-202.
9. Fraser S. Speaking addictions: Substitution, metaphor and authenticity in newspaper representations of methadone treatment. Contemporary Drug Problems 2006, 33:669-698.
10. Fraser S., valentine k. Substance and substitution: Methadone subjects in liberal societies 2008, Palgrave Macmillan, Basingstoke.
11. Galindo L., Maginnis T., Wallace G., Hansen A., Sylvestre D. Education by peers is key to success. International Journal of Drug Policy 2007, 18(5):411-416.
12. Grebely J., Dore G. Can hepatitis C virus infection be eradicated in people who inject drugs?. Antiviral Research 2014, 104:62-72.
13. Grebely J., Knight E., Genoway K.A., Viljoen M., Khara M., Elliott D., et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: A novel model incorporating multidisciplinary care and peer support. European Journal of Gastroenterology & Hepatology 2010, 22(3):270-277.
14. Grebely J., Tyndall M. Management of HCV and HIV infections among people who inject drugs. Current Opinions in HIV/AIDS 2011, 6(6):501-507.
15. Harris J., McElrath K. Methadone as social control: Institutionalized stigma and the prospect of recovery. Qualitative Health Research 2012, 22(6):810-824.
16. Harris K.J., Arnsten J., Litwin A. Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. Journal of Addiction Medicine 2010, 4(1):20-26.
17. Hellard M., Wang Y. The role of general practitioners in managing and treating hepatitis C. Medical Journal of Australia 2009, 191(10):523-524.
18. Hopwood M., Treloar C. Under the watchful eye of 'a benevolent dictator': General practitioner and patient experiences of hepatitis C treatment initiation. Australian Family Physician 2013, 42(12):900-903.
19. Keane H. Foucault on methadone: Beyond biopower. International Journal of Drug Policy 2009, 20(5):450-452.
20. Lloyd A., Clegg J., Lange J., Stevenson A., Post J., Lloyd D., et al. Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting. Clinical Infectious Diseases 2013, 56(8):1078-1084.
21. MacLachlan J., Cowie B. Liver cancer is the fastest increasing cause of cancer death in Australians. Medical Journal of Australia 2012, 197(9):492-493.
22. Morrill J.A., Shrestha M., Grant R.W. Barriers to the treatment of hepatitis C: Patient, provider and system factors. Journal of General Internal Medicine 2005, 20:754-758.
23. Norman J., Walsh N., Mugavin J., Stoove M., Kelsall J., Austin K., et al. The acceptability and feasibility of peer worker support role in community based HCV treatment for injecting drug users. Harm Reduction Journal 2008, 5(8).
24. Rance J., Treloar C. 'Not just Methadone Tracy': Transformations in service-user identity following the introduction of hepatitis C treatment into Australian opiate substitution settings. Addiction 2014, 109(3):452-459.
25. Reynolds H., Sutherland E. A systematic approach to the planning, implementation, monitoring, and evaluation of integrated health services. BMC Health Services Research 2013, 13:168.
26. Roose R., Cockerham-Colas L., Soloway I., Batchelder A., Litwin A. Reducing barriers to hepatitis C treatment among drug users: An integrated hepatitis C peer education and support program. Journal of Health Care for the Poor and Underserved 2014, 25(2):652-662.
27. Sylvestre D. Treating hepatitis C in methadone maintenance patients: An interim analysis. Drug and Alcohol Dependence 2002, 67:117-123.
28. Sylvestre D., Zweben J. Integrating HCV services for drug users: A model to improve engagement and outcomes. International Journal of Drug Policy 2007, 18(5):406-410.
29. Treloar C., Rance J., Madden A., Liebelt L. Evaluation of consumer participation demonstration projects in five Australian drug treatment facilities: The impact of individual versus organisational stability as determining factors of project progress. Substance Use and Misuse 2011, 46(8):969-979.
30. Wells K., Battaglia T., Dudley D., Garcia R., Greene A., Calhoun E., et al. Patient navigation: State of the art, or is it science?. Cancer 2008, 15(113):8. 10.1002/cncr.23815.
31. Whop L., Valery P., Beesley V., Moore S., Lokuge K., Jacka C., et al. Navigating the cancer journey: A review of patient navigator programs for Indigenous cancer patients. Asia-Pacific Journal of Clinical Oncology 2012, 8(4):e89-e96. 10.1111/j.1743-7563.2012.01532.
32. Wollhouse S., Cooper E., Pickard A. It gives me a sense of belonging: Providing integrated health care and treatment to people with HCV engaged in a psycho-educational support group. International Journal of Drug Policy 2013, 24:550-557.